6 Recommendations for research


The committee was aware that follow-up for PROFILEĀ 1014 was ongoing and that the next planned analysis of the trial would be done when median survival has been reached. The committee agreed that this additional analysis would give useful data on overall survival with crizotinib for people with untreated ALK-positive non-small-cell lung cancer.

  • National Institute for Health and Care Excellence (NICE)